SCHEMBL1099759

SCHEMBL1099759

COc1ccc(Oc2cccc(S(=O)(=O)NCC3NC(=O)NC3=O)c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 4/20 0.49
MEP1B Q16820 1/20 0.43
GHSR Q92847 1/20 0.42
CYP19A1 P11511 1/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.41
MMP3 P08254 1/20 0.41
MMP10 P09238 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
THRB P10828 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
ADAMTS5 Q9UNA0 1/20 0.39
AKR1C3 P42330 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108543 0.92 HTT (0.43) PGRMEP1BALDH1A1MAPTL3MBTL1
SCHEMBL1100507 0.92 HTT (0.43) PGRMEP1BALDH1A1MAPTL3MBTL1
SCHEMBL1100111 0.90 PGR (0.42) PGRCYP19A1GAAMAPTMEN1
SCHEMBL1108510 0.90 PGR (0.42) PGRCYP19A1GAAMAPTMEN1
SCHEMBL1108527 0.89 ALDH1A1 (0.48) PGRCYP19A1ALDH1A1MEN1KMT2A
SCHEMBL1100132 0.89 ALDH1A1 (0.48) PGRCYP19A1ALDH1A1MEN1KMT2A
SCHEMBL1100926 0.87 PGR (0.44) PGRCYP19A1ALDH1A1GAAMAPT
SCHEMBL1108519 0.87 PGR (0.44) PGRCYP19A1ALDH1A1GAAMAPT
SCHEMBL1108479 0.86 LGALS8 (0.42) PGRGAAMAPTMEN1KMT2A
SCHEMBL1099734 0.86 LGALS8 (0.42) PGRGAAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
EP-1370537-B1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2010-10-13 EP disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed
EP-1370537-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074751-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 PGR 3527/4885MEP1B 735/4885GHSR 2157/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 PGR 2805/4885MEP1B 238/4885GHSR 2215/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 PGR 860/4885MEP1B 581/4885GHSR 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.